Our previous studies have characterized Dexamethasone (Dex)-induced apoptotic signaling pathways in multiple myeloma (MM) cells; however, related transcriptional events are not fully de®ned. In the present study, gene expression pro®les of Dex-treated MM cells were determined using oligonucleotide arrays. Dex triggers early transient induction of many genes involved in cell defense/repair-machinery. This is followed by induction of genes known to mediate cell death and repression of growth/survival-related genes. The molecular and genetic alterations associated with Dex resistance in MM cells are also unknown. We compared the gene expression pro®les of Dex-sensitive and Dex-resistant MM cells and identi®ed a number of genes which may confer Dexresistance. Finally, gene pro®ling of freshly isolated MM patient cells validates our in vitro MM cell line data, con®rming an in vivo relevance of these studies. Collectively, these ®ndings provide insights into the basic mechanisms of Dex activity against MM, as well as mechanisms of Dex-resistance in MM cells. These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival.
Introduction
Multiple Myeloma (MM) will have aected 14 000 new individuals in the United States in 2001 and remains incurable, despite all available therapies. Dexamethasone (Dex) is the most commonly used drug in the treatment of MM (Alexanian et al., 1992) . Our prior studies have extensively characterized signaling pathways activated during Dex-induced apoptosis (Chauhan et al., 1997a (Chauhan et al., ,b, 1999 (Chauhan et al., , 2000 , as well as those cascades mediating Dex-resistance conferred by interleukin-6 (IL-6) (Chauhan et al., 2000) . To date, however, the genetic events that accompany Dextriggered apoptosis in MM cells remain largely unknown. Moreover, alterations in the signaling cascades from cell surface 44tyrosine kinases/phosphatases 44gene transcription 44gene products mediating Dex-resistance in MM cells are also unde®ned. Identi®cation and characterization of these upstream signaling proteins, as well as downstream eector genes and their products, may identify novel targets and provide the framework for improved therapeutic uses of Dex.
In MM, tumor cells are predominantly localized in the bone marrow (BM) microenvironment due to adherence both to extracellular matrix proteins and to bone marrow stromal cells (BMSCs). This interaction between tumor cells and BMSCs both triggers production of cytokines mediating autocrine and paracrine growth and survival of MM cells, and protects MM cells against Dex-induced apoptosis Chauhan et al., 1996; Anderson, 2001) . For example, adherence of tumor cells to BMSCs upregulates Nuclear Factor-kappa B (NF-kB)-dependent interleukin-6 (IL-6) transcription and secretion within BMSCs Chauhan et al., 1996) ; moreover, MM cells in the marrow milieu secrete cytokines, i.e., transforming growth factor-b (TGF-b) and tumor necrosis factor a (TNF-a), which further enhance IL-6 transcription and secretion from BMSCs Hideshima et al., 2001a) . This is of central importance since IL-6 induces growth, survival, and drug resistance in MM cells. Speci®cally, Dex-induced apoptosis in MM cells is completely abrogated by IL-6 (Lichtenstein et al., 1995; Chauhan et al., 1997a Chauhan et al., ,b, 1999 Chauhan et al., , 2000 Anderson, 2001) . However, the transcriptional and signaling cascades whereby IL-6 and other cytokines in the BM microenvironment protect against druginduced apoptosis in MM cells are not yet delineated.
The recent advent of cDNA microarray technology permits observation of simultaneous changes in the expression pattern of a wide variety of genes. For example, recent studies have utilized the cDNA microarray methodology to improve diagnosis and classi®cation of cancer (Golub et al., 1999) and to de®ne novel mechanisms of drug actions (Joyce et al., 2001; Kudoh et al., 2001; Zimmermann et al., 2000; Der et al., 1998) . In the present study, we utilized cDNA microarray technology: (1) to identify genes induced in response to Dex treatment; (2) to compare gene expression pro®les in Dex-sensitive (MM.1S) versus Dex-resistant (MM.1R) MM cells; and (3) to identify and compare gene expression pro®les in MM patient cells versus normal BM mononuclear cells (BMMCs). Our study demonstrates that Dex triggers early transient induction of genes encoding for stress response and repair, followed by induction of apoptotic genes associated with repression of growth and survival genes. Comparative analysis of gene expression pro®les of Dex-sensitive (MM.1S) versus Dex-resistant (MM.1R) cells demonstrates dierential expression of genes that may confer Dex-resistance. Finally, the gene expression pro®les of freshly isolated patient MM cells validates our in vitro MM cell line data, con®rming an in vivo relevance of these studies. These studies elucidate mechanisms of both Dex anti-MM activity and Dex resistance, and provide the framework for novel treatment strategies to enhance its ecacy and overcome drug resistance.
Results and Discussion
The cellular response to Dex includes growth arrest and induction of apoptosis in MM cells (Chauhan et al., 1997a,b; Feinman et al., 1999) ; however, the genetic events that control these events are not fully characterized. To delineate speci®c alterations in gene expression induced by Dex, MM.1S MM cells were treated with Dex (10 mM) and harvested at dierent time intervals. Total cellular RNA was prepared and subjected to cDNA microarray, followed by data analysis using DNA Chip Analyser (DChip). The results identi®ed genes which are either transiently induced or repressed in response to Dex treatment. To interpret and organize the data, dierentially expressed cDNAs were grouped according to their temporal expression pattern using an hierarchical clustering algorithm (Eisen et al., 1998) (Li and Wong, 2001) .
Genes regulated in response to Dex
A total of 94 genes demonstrated signi®cantly (P50.05) altered expression pattern, including genes that are either induced (A) or suppressed (B) in response to Dex treatment (Figure 1 ). Gene expression pro®les obtained from repeat array experiments served as internal controls for reproducibility of the observed temporal changes in gene expression. Most regulated genes demonstrated smooth curves of expression ratios, providing further con®rmation of individual timepoint measurements. The cell viability, as assessed by Trypan blue exclusion, was 490% in Dex-treated cells. As can be seen in Table 1 , treatment of MM.1S cells with Dex for 24 h signi®cantly alters the expression of genes encoding apoptotic and anti-apoptotic signaling proteins, transcription factors, cell surface proteins, as well as membrane-associated proteins involved in cellular adhesion and signaling.
As shown in Figure 1 , the expression pattern of multiple genes changed progressively with time of Dex treatment. First, relatively few genes were upregulated early (4 h) after Dex treatment, suggesting that the initial stress response is not mediated through gene induction. Second, various apoptosis-related genes, including caspase-like apoptosis regulator (CLARP), Tis11d, and MAD3/IkB-a are detectable early (2 h) and peak at 24 h ( Figure 1 , Table 1 , and Figure 2a ). Third, Dex treatment of MM.1S MM cells also induced genes which aect growth and survival ( Figure  1 , and Table 1 ). For example, Dex induces genes encoding for MAP Kinase phosphatase (MKP), which inactivates growth-related MAP Kinase. We have previously shown that both IL-6 (Ogata et al., 1997) and vascular endothelial growth factor (VEGF) (Podar et al., 2001) trigger MM cell growth via the MAPK signaling cascade (Chauhan et al., 1997b) , and that Dex downregulates these growth kinases in MM cells (Chauhan et al., 1997b) . In contrast, anti-apoptotic genes, such as Bcl-xL, were signi®cantly downregulated in MM cells in response to Dex treatment (Figure 2a) . Fourth, Dex altered expression of many protooncogenes (Table 1) . For example, Dex represses the expression of both c-myc and FUSE binding protein 2 (FBP2), a known transcriptional activator of c-myc.
Finally, cDNA microarray also demonstrated alterations in novel genes encoding for nuclear proteins, which have not previously been associated with Dex responses in MM cells (Table 1) . For example, Dex induces the expression of Nuclear antigen H731/Pdcd4 gene, which inhibits tumor promoter-induced neoplastic transformation and promotes tumor progression (Yang et al., 2001) . Dex also induces mRNA for AP3 Sigma complex, a clarithin-associated adaptor complex known to mediate the tracking of membrane protein to lysosome-related organelles (Dell'Angelica et al., 1997) . The alterations in the expression of these genes suggests their role during Dex-induced apoptosis in MM cells.
Effects of Dex on NF-kB pathway
NF-kB is ubiquitously expressed and involved in activation of various genes in response to in¯ammation, infections, and other stress agents. NF-kB is normally sequestered in the cytoplasm of unstimulated cells and requires translocation into the nucleus to function. The subcellular location of NF-kB is controlled by a family of IkB inhibitory proteins, which bind to NF-kB and block Oncogene Dexamethasone-induced genes in multiple myeloma D Chauhan et al its nuclear translocation. Upon stimulation with extracellular inducers of NF-kB, such as TNF-a, IL-6 or IL1b, IkB is proteolytically degraded by proteasomes, allowing translocation of NF-kB to the nucleus where it regulates gene transcription (Karin and Ben-Neriah, 2000).
As noted above, cDNA microarray showed that MAD-3/IkB-a is upregulated in response to Dex in MM.1S cells (Figure 1 and Table 1 ). To determine whether increases in MAD-3/IkB-a mRNA correlate with increased protein levels, MM.1S cells were treated with Dex for 12, 24, 48 and 72 h. Total protein lysates were subjected to SDS ± PAGE analysis, transferred onto a ®lter, and immunoblotted with anti-MAD-3/ IkB-a or anti-tubulin Abs. As shown in Figure 2b , (upper and bottom panels), Dex triggered an increase in MAD-3/IkB-a protein levels, without any alterations in tubulin. Since MAD-3/IkB-a protein binds to NFkB and prevents its nuclear translocation and activation, we next examined whether Dex-induced MAD-3/ IkB-a prevents NF-kB function in MM.1S cells using an electromobility shift assay (EMSA) of NF-kB DNA binding in nuclear extracts from Dex-treated MM.1S cells. As in our and other previous studies (Kohler et al., 2001; Hideshima et al., 2001a,b) , TNF-a was used to induce NF-kB activation in MM.1S cells, in the presence or absence of Dex. As shown in Figure 2c , Dex decreases DNA binding following TNF-a induction of NF-kB in MM.1S cells. Speci®city of the EMSA was con®rmed with supershifts to p65 antibody, as well as by competition with cold consensus sequence (data not shown). These ®ndings are in concert with studies demonstrating inhibition of NF-kB triggered by Dex in other cell types (Rowland et al., 2001) .
The current microarray analysis also revealed that genes modulated by NF-kB (Pahl et al., 1999) , such as superoxide dismutase (SOD), c-myc, Bcl-xL, and MIP1a, were altered by Dex treatment: 12 of 93 genes signi®cantly modulated by Dex were downstream targets of NF-kB. These data further con®rm NF-kB signaling cascades as targets mediating Dex anti-MM activity ( Figure 2d ) and suggest that novel drugs Our recent study has utilized PS-341, a proteasome inhibitor which prevents MAD-3/IkB-a degradation and inhibits NF-kB activity, to enhance the inhibitory eects of Dex on NF-kB inhibition and apoptosis in MM cells (Hideshima et al., 2001b) .
Effect of Dex on interleukin-6 receptor (IL-6R) gene
In the present study, we focused on genes that are known to play an important role in MM pathogenesis, including genes for interleukin-6 receptor (IL-6R) and transforming growth factor receptor type II (TGFbRII). Speci®-cally, we and others have shown that IL-6 mediates autocrine and paracrine growth of MM cells Klein et al., 1989; Urashima et al., 1996; Chauhan et al., 1996; Uchiyama et al., 1993; Levy et al., 1996) . IL-6 not only triggers MM cell growth via the MAPK signaling cascade (Ogata et al., 1997) , but also blocks Dex-induced apoptosis via activation of PI-3 kinase/Akt signaling (Hideshima et al., 2001b ) and a tyrosine phosphatase, SHP2 (Chauhan et al., 2000) . Based upon these observations, multiple therapies for MM have attempted to block IL-6 signaling, including the use of mAbs to IL-6 , as well as IL-6R blockade (Tassone et al., 2000; Juge-Morineau et al., 1995) .
In the present study, cDNA microarray analysis demonstrates that Dex triggers a transient upregulation IL-6R mRNA in MM.1S cells: peak levels of IL-6R of mRNA were observed at 4 and 24 h after Dex treatment, followed by a decrease at 72 h ( Figure 3a) . These results were con®rmed by Northern blot analyses: low levels of IL-6R mRNA were observed in untreated MM.1S cells (Figure 3b, upper panel) ; Dex induced a signi®cant increase (10 ± 12-fold, as measured by densitometric analysis) in IL-6R mRNA at 12 and 24 h ( Figure 3b , upper panel); and IL-6R mRNA levels decreased at longer exposures i.e., 72 h, to Dex. No changes in b-actin mRNA levels were observed ( Figure 3b , lower panel). Our ®nding that Dex enhances the expression of IL-6R mRNA levels is in concert with previous studies (Mori et al., 1998; Fischer et al., 1996) .
In order to further de®ne the functional sequelae of changes in IL-6R mRNA expression, we used both Western blot and¯ow cytometric analysis to assay for associated changes in IL-6R protein expression. MM.1S cells were treated with Dex (10 mM), harvested at dierent time intervals, and total cell lysates then subjected to immunoblot analyses with anti-IL-6R Ab. Dex induced a transient increase in IL-6R protein, which was maximal at 12 and 24 h, followed by a decline at longer intervals of Dex exposure (72 h) (Figure 3d ). Taken together, these ®ndings suggest that treatment of MM cells with Dex triggers a transient upregulation of both IL-6R mRNA and protein levels, characteristic of a stress response. Since our and other prior studies have shown that IL-6 blocks Dex-induced apoptosis in MM cells (Chauhan et al., 2000; Hardin et al., 1994) , the current study shows that Dex not only triggers a death signal, but also simultaneously induces a protective signal, mediated by increased IL-6R on the MM cell surface, enhanced IL-6 binding, and related protection against Dex-induced apoptosis (Figure 3e ). Collectively, these ®ndings provide further insights into the mechanism of Dex action and its crosstalk with survival and growth signaling pathways in MM cells.
Effect of Dex on TGF-b receptor gene
Although the role of IL-6 in the pathophysiology of MM is extensively studied (Anderson and Lust, 1999) , the mechanism whereby other cytokines triggering MM cell growth, either directly or indirectly by regulating IL-6, is less well characterized. Our prior study demonstrated that: (1) TGF-b is produced by both MM cells and bone marrow stromal cells (BMSCs) and can trigger IL-6 secretion in MM cells and BMSCs, MoAb inhibits IL-6 secretion by BMSCs, as well as the increments in IL-6 secretion induced by MM cell adhesion to BMSCs . These studies therefore con®rm the role of TGF-b in triggering IL-6 secretion and suggest an indirect mechanism whereby it enhances growth and survival of MM cells. In the present study, cDNA microarray analyses demonstrated that Dex treatment of MM-1S MM cells induces a transient increase in TGF-b receptor type II (TGF-bRII) mRNA levels at 24 h, followed by signi®cant decreases in TGF-bRII mRNA expression at 72 h ( Figure 4a , and Table 1 ). These results were con®rmed by Northern blot analyses: levels of TGF-bRII transcripts peak at 24 h and decline at longer periods of Dex exposure ( Figure  4b) ; no changes are observed in the b-actin mRNA levels. The transient increase in TGF-bRII expression early after Dex treatment of MM cells is consistent with a protective mechanism, whereby increased TGFbRII on the MM cell surface facilitates enhanced TGFb binding, thereby triggering transcription and secretion of IL-6 and related protection against Dexinduced apoptosis.
Collectively, these cDNA microarray analyses of Dex-treated MM cells provide a signature pro®le of genes that can be targeted for improving ecacy of Dex treatment in this disease. For example, our ®ndings suggest that a combination of Dex with anti-IL6R or anti-TGF-bRII antibody may be more eective in the treatment of MM than Dex alone. Similarly, the ®nding that Dex induces MAD-3/IkB-a gene suggests that use of drugs or small molecules targeting MAD-3/IkB-a in combination with Dex may enhance ecacy of Dex therapy in MM. In this context, our recent study demonstrates that the proteasome inhibitor PS-341 prevents MAD-3/IkB-a degradation and enhances Dex-induced NF-kB inhibition, as well as apoptosis, in MM cells (Hideshima et al., 2001c) . Based on these ®ndings, an ongoing multicenter clinical trial is evaluating a combination of Dex and PS-341 therapy for MM.
Genes conferring Dex-sensitivity and Dex-resistance in MM One of our major current research eorts is directed to delineate mechanisms mediating chemoresistance in (Anderson, 2001 ). Drug resistance is likely to involve alterations in diverse groups of genes with distinct biochemical functions. Moreover, acquisition of drug resistance while on therapy may be related to induction of genes or selection for resistant tumor cells. To date, however, the molecular and genetic alterations conferring Dex resistance in MM cells are not well de®ned. We therefore next utilized cDNA microarrays to de®ne a`signature' gene expression pro®le of Dex-sensitive versus Dex-resistant MM cells. For these studies we compared MM.1S cells, which are sensitive to Dex, with a derivative cell line MM.1R, which is resistant to Dex (Chauhan et al., 1999 (Chauhan et al., , 2000 (Table 2) .
Differential expression pattern of glucocorticoid receptor (GR) gene
Prior studies have linked Dex-responsiveness to glucocorticoid receptor (GR) levels, and ectopic expression of wild-type GR in GR-de®cient cells restores Dex-sensitivity (Moalli et al., 1992 (Moalli et al., , 1993 Goldman-Leikin et al., 1989) . Furthermore, a prior study utilizing Dex-sensitive (MM.1S) and Dex-resistant (MM.1R) cells has shown that MM.1S cells express high levels (approximately 50 000 GR per cell) of the full-length 7.1-kb GR mRNA. In contrast, Dex resistant MM.1R cells express the 7.1-kb GR mRNA at low levels. In the present study, comparative analysis of gene pro®les of Dex-sensitive (MM.1S) and Dexresistant (MM.1R) cells demonstrate signi®cantly lower levels of GR in MM.1R cells. Speci®cally, DChip analysis of microarray data show that the expression of GR-a, but not of the alternatively spliced GR (GR-b), is markedly reduced (4.5-fold) in MM.1R MM cells versus MM.1S MM cells (Table 2) . Northern blot analysis con®rms signi®cantly (fourfold, as determined by densitometric analysis) reduced levels of GR-a transcripts in MM.1R cells versus MM.1S MM cells, whereas no change in b-actin mRNA levels was observed (Figure 5a ). Our prior studies demonstrating the lack of responsiveness to Dex in MM.1R cells (Chauhan et al., 2000) , coupled with the signi®cantly low levels of GRa in MM.1R MM cells observed in this study, suggest that downregulation of GRa may confer Dex-resistance in MM cells.
Differential expression pattern of heat shock family proteins (Hsps)
The current microarray analyses also showed that genes encoding for stress proteins, such as heat shock proteins (Hsps), are upregulated in MM.1R cells versus MM.1S cells. Hsps are a set of highly conserved protein subfamilies, based upon their molecular weight (Jaattela et al., 1999) , i.e., hsp90, hsp72, hsp60, or hsp28. Overexpression of hsp72 protects cells from apoptosis, both upstream and downstream of eector caspase activation (Jaattela et al., 1998) . Other studies have shown that hsp28 is constitutively expressed in tumor cells at speci®c stages of development and dierentiation. In the present study, both hsp28 and hsp72 mRNAs were found to be upregulated in MM.1R cells compared to MM.1S cells (Table 2) . To determine whether changes in hsp mRNA levels correlate with altered protein levels, total protein lysates from MM.1S cells and MM.1R cells were subjected to SDS ± PAGE analysis, transferred onto a ®lter, and immunoblotted with anti-hsp28, anti-hsp72, or anti-tubulin Abs. A 4 ± 6-fold higher level of both hsp28 and hsp72 protein expression was present in Dex-resistant MM.1R cells compared to Dex-sensitive MM.1S cells (Figure 5d ,e, upper panels respectively).
Reprobing the immunoblot with anti-tubulin Ab con®rmed equal protein loading (Figure 5d ,e, lower panels). Various stress stimuli not only trigger apoptotic or death signals, but also simultaneously induce protective signaling pathways. For example, oxidative stress, staurosprine, and cytotoxic drugs (Mehlen et al., 1996; Garrido et al., 1997) induce overexpression of hsp28 in tumor cells, thereby protecting against apoptosis and increasing their tumorigenesis (Garrido et al., 1998) . In the present study, we therefore next examined whether treatment of MM.1S cells with Dex induces hsp28. Our cDNA microarray data showed an induction of hsp28 in MM.1S cells in response to Dex (Table 1) , which was associated with an increase in hsp28 protein levels (data not shown). Several mechanisms for anti-apoptotic activity of hsp28 have been reported: hsp28 increases glutathione level to protect against anti-oxidants; and hsp28, like Bcl2, blocks chemotherapy-induced activation of procaspase-9 and -3 in human leukemic cells (Garrido et al., 1999) . These and the current studies suggest that neutralizing the anti-apoptotic eects of hsp28 or hsp72, i.e., inhibiting their expression by antisense oligonucleotides, may sensitize MM cells to Dex or overcome Dexresistance. Conversely, pharmacological stimuli or cytokines that trigger hsp28 expression may protect cells from stress agents.
Differential expression of ubiquitin-proteasome/NF-kB pathway related genes
Our cDNA pro®ling analysis demonstrates signi®cantly higher ubiquitin and ubiquitin conjugating enzyme mRNA levels in MM.1R cells than in MM.1S MM cells ( Table 2) . As shown in Figure 5b , Northern blot analysis con®rms that ubiquitin expression is 3 ± 4-fold higher, as determined by densitometric analysis, in MM.1R MM cells versus MM.1S MM cells. Increased expression of ubiquitin-related genes is an early event in tumorigenesis and has been associated with a drugresistant phenotype in other cell systems (Desai et al., 2000; Spataro et al., 1998) . For example, it has been reported that some ubiquitin-conjugating enzymes, most notably cdc34, speci®cally degrade IkB and mediate resistance to Dex-induced apoptosis (Wu and Ghosh, 1999) . It is possible that some of the ubiquitin conjugating enzymes identi®ed in our study may similarly protect against Dex by activating the degradation of Dex-induced MAD-3/IkB-a in MM cells. Since multiple studies have linked NF-kB activation with survival and proliferation in tumor cells (Bours et al., 2000 ; Barkett and Gilmore, 1999), we next (Petro and Khan, 2001; Bajpai et al., 2000) . In the present study, both mRNA (Table 1) as well as protein levels ( Figure  5c ) of BTK were upregulated in MM.1R cells compared to MM.1S cells, suggesting that it may also contribute to Dex-resistance and enhanced survival of MM.1R cells.
Our microarray results also showed that G-protein coupled receptor V28 or CX3CR1 mRNA is more highly expressed in MM.1R cells compared to MM.1S cells (Table 2 ). CX3CR1 is recognized by the unique, membrane bound chemokine Fractalkine (FKN, CX3CL1) (Combadiere et al., 1998) , and a recent study demonstrated that activation of CX3CR1 by FKN mediates both leukocyte migration and adhesion (Fraticelli et al., 2001; Volin et al., 2001) . The observation that adhesion of MM cells to BMSCs triggers NF-kB dependent IL-6 secretion in BMSCs and confers drug-resistance (Anderson, 2001; Chauhan et al., 1997b) , coupled with the present demonstration that MM.1R cells express higher CX3CR1 mRNA levels than MM.1S cells, implicate CX3CR1-FKN interactions in mediating Dex resistance.
Taken together, these results demonstrate that thè signature' gene expression pro®les of Dex-sensitive and Dex-resistant MM cells are distinct. They provide the basis for further elucidation of mechanisms of Dex resistance, as well as the framework for novel therapeutic approaches based upon targeting altered genes to overcome the Dex-resistant phenotype.
Gene profiles from MM patient and normal donor bone marrow mononuclear cells
Having demonstrated the cDNA pro®le of Dex-treated MM.1S cells and compared cDNA pro®les of Dexsensitive versus Dex-resistant MM cells, we next asked whether puri®ed MM cells obtained from patients resistant to Dex have similar gene expression pro®les. Microarray analysis of six freshly isolated patient MM cells were compared to normal donor BMMCs (Table  3) . A number of genes whose expression was altered with Dex treatment of MM.1S cells in vitro, including IL-6R, MIP-1a, syndecan-1, fas/APO-1, and ubiquitin ligase, were also more highly expressed in these patient MM samples than in normal BMMCs. Genes related to ubiquitin-proteasome pathway were also highly expressed, consistent with the drug-resistant phenotype in MM patient cells. The ®ndings that UbiquitinProteasome pathway related genes are upregulated in response to Dex treatment of MM.1S cells, coupled with their high expression in Dex-resistant patient MM cells, further supports a role for the UbiquitinProteasome pathway in mediating Dex-resistance. Comparison of microarray pro®les of Dex sensitive versus Dex resistant patient MM cells is ongoing to further address this issue.
Our microarray comparison also demonstrated that genes encoding for growth-related signaling proteins, such as ERK3 and BTK, were more highly expressed in MM patient cells than in normal BMMCs. In contrast, the expression of anti-proliferative genes, such as B cell translocation gene-1 (BTG-1) (Matsuda et al., 2001) , was signi®cantly reduced in MM patient cells. Genes for known MM cell adhesion molecules, i.e., syndecan-1 and integrin-b5 , were more highly expressed (6.4-and 2.1-fold, respectively) in MM patient cells than BMMCs. Since we and others have shown that adherence of patient MM cells to BMSCs promotes their growth and survival , microarray studies focusing on MM cell-BMSC interactions may further suggest mechanisms regulating MM cell growth and survival in the BM milieu.
In summary, we used cDNA microarray analysis to identify Dex-responsive genes in MM cells and to demonstrate a dierential expression pattern of genes in Dex-sensitive versus Dex-resistant cells. These studies have provided the framework for ongoing pro®ling to further identify genes predicting for Dex responsiveness or conferring resistance to Dex therapy. Ultimately, they will provide the rationale for optimal use of Dex, alone or in combination treatment approaches, to improve patient outcome in MM.
Materials and methods

Cell culture and reagents
Human MM.1 cell line was established from the peripheral blood of a 42-year-old woman with an IgA-l MM (Goldman- Leikin et al., 1989) . MM.1 cells have been characterized by cytochemical,¯ow cytometric, immunohistochemical, as well as Southern and Northern blotting analyses and shown to be an Epstein-Barr virus (EBV)-negative MM cell line which exclusively secretes lambda light chain (GoldmanLeikin et al., 1989) . MM.1S, a sensitive clone of MM.1 (IC 50 =0.05 mM), was isolated using the Salmon Hamburger soft agar technique (Salmon, 1984) . A population of MM.1 cells resistant to glucocorticoid-induced cytolysis derived by continuous exposure to Dex (MM.1R cells) maintains 490% viability when cultured in the presence of Dex (0.05 mM) (Moalli et al., 1992) . MM.1S (Dex-sensitive) and MM.1R (Des-resistant) cells (Moalli et al., 1992 (Moalli et al., , 1993 Krett et al., 1997) were grown in RPMI 1640 medium supplemented with 10% heat inactivated fetal-bovine serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM Lglutamine. MM.1S cells were treated with Dex (Sigma Chemical Co, St. Louis, MO, USA) for 2, 4, 24, 48, or 72 h, and harvested. Total RNA was isolated from 10 7 lysed cells using TRIzol Reagent (Life Technologies, Rockville, MD, USA), and double-stranded cDNA was prepared from 5 mg of total RNA using Life Technologies Superscript choice system and an oligo (dT) anchored T7 primer. Cell viability was con®rmed by Trypan blue exclusion.
Mononuclear cells were isolated from six patients with MM by Ficoll-Hypaque density gradient centrifugation and incubated with HB-7 (anti-CD38) MoAb-biotin-streptavidin and 2H4 (anti-CD45RA) MoAb-¯uorescein isothiocyanate on ice (Chauhan et al., 1997b) . Tumor cells (96+2% CD38+45RA7) were isolated using an Epics C cell sorter (Coulter Electronics, Hialeah, FL, USA), washed, and resuspended in regular growth medium.
Preparation of biotinylated probes and hybridization on microarrays
Aymetrix huGene FL TM arrays (Santa Clara, CA, USA) containing 6800 genes were used for mRNA expression pro®ling. Biotinylated RNA was synthesized using the BioArray RNA transcript labeling kit (Enzo, Farmingdale, NY, USA) with biotin-11-CTP and biotin-16-UTP for 5 h at 378C. In vivo transcription products were puri®ed using RNeasy columns (Quiagen, Valenica, CA, USA). Biotinylated RNA was then treated for 35 min at 948C in a buer containing 200 mM Tris acetate, pH 8.1, 500 mM potassium acetate, and 150 mM magnesium acetate.
Aymetrix huGene FL TM and U95A arrays were hybridized with biotinylated in vivo transcription products (10 mg/ Chip) for 16 h at 458C using the manufacturer's hybridization buer. Fluidic station 400 (Aymetrix, Santa Clara, CA, USA) was used for washing and staining the arrays. Due to the size-reduced hybridization features for the huGene FL TM array, a three-step protocol was used to enhance detection of the hybridized biotinylated RNA: incubation with streptavidin-phycoerythrin conjugate, labeling with an anti-streptavidin goat biotinylated Ab (Vector Laboratories, Burlingam, CA, USA); and staining again with streptavidin-phycoerythrin conjugate. DNA Chips were then analysed using the Gene Array Scanner (Aymetrix, Santa Clara, CA, USA). The excitation source was an argon ion laser, and the emission was detected by a photomultiplier tube through a 570-nm long pass ®lter.
Digitized image data were processed using version 4.0 GeneChip software (Aymetrix), and image data ®les were processed using the DNA Chip Analyser (DChip) (Li and Wong, 2001) . Genes dierentially modulated with a 95% con®dence level were considered signi®cant. For MM patient data, GeneChip Microarray Suite 4.0 software was used, and 5twofold changes were considered signi®cant. Internal controls of housekeeping genes and a test chip trial were run prior to evaluation of MM cell line and patient samples.
Northern blot analyses
Northern blot analyses were performed as previously described (Chauhan et al., 1994) . Brie¯y, total RNA (20 mg/lane) was subjected to electrophoresis through a 1% agarose/2.2 mol/L formaldehyde gel, transferred to nitrocellulose ®lters, and hybridized to 32 P-labeled DNA probes for IL-6R , TGF-brII (Chaudhry et al., 1994) , ubiquitin, glucocorticoid receptor (GR), and chicken b-actin probe . Hybridizations were performed at 428C for 24 h in 50% (vol/vol) formamide, 26SSC (SSC: 0.15 mol/L sodium chloride, 0.015 mol/L sodium citrate), 16Denhardt's solution, 0.1% (wt/vol) sodium dodecyl sulfate (SDS), and 200 mg/ml salmon sperm DNA. The ®lters were washed twice in 26SSC-0.1% SDS at room temperature and then in 0.16SSC-0.1% SDS at 608C for 30 min, before exposure to Kodak X-Omat XAR ®lm (Eastman Kodak, Rochester, NY, USA) using an intensifying screen. The autoradiograms were scanned using an LKB producter (Bromma, Sweden) Ultrascan XL laser densitometer and analysed with the Gelscan software package. Signal intensity was determined in a linear range and normalized to that for actin.
Western blot analyses
Cell lysates were prepared as previously described (Chauhan et al., 1997a) . Brie¯y, equal amounts of proteins (250 ± 300 mg) were resolved by 10% SDS ± PAGE and transferred to nitrocellulose membranes. Proteins were then transferred to nitrocellulose ®lters, blocked by incubation in 5% dry milk in PBST (0.05% Tween-20 in PBS), and probed with the indicated Abs. Blots were then developed by enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL, USA).
Flow cytometric analyses
Cell surface antigen expression was analysed by direct immuno¯uorescence (FACScan, Becton Dickinson, Mountain View, CA, USA). Cells were washed twice with culture media and incubated for 30 min on ice with each test mAb diluted to the optimal concentration for immunostaining. Labeled cells were then washed, ®xed in 1% paraformaldehyde, and analysed for¯uorescence staining using FITC-IL-6R mAbs (Coulter/Immunotech, Miami, FL, USA).
